Hudson Value Partners LLC Has $5.48 Million Stake in Johnson & Johnson (NYSE:JNJ)

Hudson Value Partners LLC lessened its position in Johnson & Johnson (NYSE:JNJ) by 5.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 34,985 shares of the company’s stock after selling 1,898 shares during the period. Johnson & Johnson makes up about 2.6% of Hudson Value Partners LLC’s investment portfolio, making the stock its 6th biggest holding. Hudson Value Partners LLC’s holdings in Johnson & Johnson were worth $5,484,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Pathway Financial Advisors LLC increased its position in shares of Johnson & Johnson by 4.3% during the fourth quarter. Pathway Financial Advisors LLC now owns 5,438 shares of the company’s stock worth $852,000 after acquiring an additional 226 shares in the last quarter. Daiwa Securities Group Inc. increased its position in shares of Johnson & Johnson by 5.5% during the fourth quarter. Daiwa Securities Group Inc. now owns 297,850 shares of the company’s stock worth $46,685,000 after acquiring an additional 15,490 shares in the last quarter. OneAscent Financial Services LLC increased its position in shares of Johnson & Johnson by 82.8% during the fourth quarter. OneAscent Financial Services LLC now owns 9,838 shares of the company’s stock worth $1,542,000 after acquiring an additional 4,457 shares in the last quarter. Vestmark Advisory Solutions Inc. increased its position in shares of Johnson & Johnson by 12.7% during the fourth quarter. Vestmark Advisory Solutions Inc. now owns 19,587 shares of the company’s stock worth $3,070,000 after acquiring an additional 2,201 shares in the last quarter. Finally, TrueMark Investments LLC bought a new stake in shares of Johnson & Johnson during the fourth quarter worth $1,458,000. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Morgan Stanley lowered their price objective on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 17th. Royal Bank of Canada restated an “outperform” rating and set a $175.00 target price on shares of Johnson & Johnson in a report on Wednesday. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Monday, May 6th. Finally, Bank of America reduced their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $175.86.

Johnson & Johnson Stock Performance

JNJ stock traded down $2.73 during trading hours on Friday, reaching $146.97. The stock had a trading volume of 9,520,576 shares, compared to its average volume of 7,234,254. The stock has a market capitalization of $353.71 billion, a PE ratio of 9.16, a price-to-earnings-growth ratio of 2.44 and a beta of 0.55. The stock has a 50-day simple moving average of $151.31 and a 200 day simple moving average of $155.07. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $175.97. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.64 by $0.07. The company had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The company’s revenue was up 2.3% on a year-over-year basis. During the same period in the prior year, the firm earned $2.68 earnings per share. Analysts predict that Johnson & Johnson will post 10.64 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be given a $1.24 dividend. The ex-dividend date of this dividend is Monday, May 20th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a dividend yield of 3.37%. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.